Innovative Technology PyrAmes specializes in continuous, non-invasive blood pressure monitoring technology, with FDA clearance for its Boppli platform, positioning it as a leader in critical care solutions for vulnerable populations such as critically-ill infants and seniors.

Strong Regulatory Progress The company has achieved significant regulatory milestones including FDA Breakthrough Device Designation and 510(k) clearance, indicating a reliable pathway for market penetration and a compelling value proposition for hospitals and healthcare providers.

Recent Industry Recognition Awards like the AAP SOATT Pediatric Device Award and the Texas HALO FUND Corona Award highlight credibility and innovative excellence in pediatric healthcare, which can facilitate trust and adoption among pediatric and neonatal care centers.

Growing Market Presence Participation in global accelerators and strategic partnerships like Plug & Play Ventures expand PyrAmes’ reach internationally, creating sales opportunities in diverse healthcare markets focusing on digital health and pediatric care solutions.

Funding and Revenue Outlook With recent Series A funding of $6 million and revenue estimates between $1 million and $10 million, PyrAmes is poised for scaling growth, providing opportunities for strategic sales collaborations with larger healthcare device distributors and global healthcare organizations.